Angiogenesis in rheumatoid arthritis

Autoimmunity

Volumn 42, Issue 7, 2009, Pages 563-573

  Szekanecz, Zoltán ^a   Besenyei, Timea ^a   Paragh, György ^a   Koch, Alisa E ^b,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Angiostasis therapy; Rheumatoid arthritis; Vascular endothelial growth factor

Indexed keywords

2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; ENDOSTATIN; FUMAGILLIN; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; PACLITAXEL; PROTEINASE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; INFLAMMATION; NEOVASCULARIZATION (PATHOLOGY); REVIEW; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ARTHRITIS, RHEUMATOID; BLOOD VESSELS; CELL ADHESION MOLECULES; CYTOKINES; EXTRACELLULAR MATRIX; HUMANS; INFLAMMATION MEDIATORS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71049131072     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930903143083     Document Type: Review

References (118)

1. Koch AE. Angiogenesis: Implications for rheumatoid arthritis. Arthritis Rheum 1998;41:951-962.
2. Szekanecz Z, Koch AE. Endothelial cells in inflammation and angiogenesis. Curr Drug Targ 2005;4:319-323.
3. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 2008; 10:224.
4. Foster W, Carruthers D, Lip GY, Blann AD. Relationship between endothelial inflammatory and angiogenesis markers in rheumatoid arthritis: Implications for cardiovascular pathophysiology. Thromb Res 2009;4:659-664.
5. Szekanecz Z, Koch AE. Mechanism of disease: Angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol 2007;3: 635-643.
6. Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 2007;3:434-442.
7. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-447.
8. Szekanecz Z, Koch AE. Chemokines and angiogenesis. Curr Opin Rheumatol 2001;13:202-208.
9. Naumov GN, Folkman J, Straume O, Akslen LA. Tumorvascular interactions and tumor dormancy. APMIS 2008; 116:569-585.
10. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006;19:335-344.
11. Jakobsson L, Claesson-Welsh L. Vascular basement membrane components in angiogenesis-an act of balance. Sci World J 2008;8:1246-1249.
12. Veale DJ, Fearon U. Inhibition of angiogenic pathways in rheumatoid arthritis: Potential for therapeutic targeting. Best Pract Res Clin Rheumatol 2006;20:941-947.
13. Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol 2006;18: 268-276.
14. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007;19: 289-295.
15. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-4156.
16. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signaling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007;16:83-107.
17. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008;41:278-286.
18. Hernandez GL, Volpert OV, Iñiguez MA, Lorenzo E, Martínez-Martínez S, Grau R, Fresno M, Redondo JM. Selective inhibition of vascular endothelial growth factormediated angiogenesis by cyclosporin A: Roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001;193:607-612.
19. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005;17: 293-298.
20. Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum 2007;56: 1787-1797.
21. Kim HR, Park MK, Cho ML, Yoon CH, Lee SH, Park SH, Leng L, Bucala R, Kang I, Choe J, Kim HY. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 2007;34:927-936.
22. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: Rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007;9(Suppl. 2):S3.
23. Haq A, El-Ramahi K, Al-Dalaan A. Serum and synovial fluid concentrations of endothelin-1 in patients with inflammatory arthritides. J Med 1999;30:51-60.
24. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-11398.
25. Manley PW, Martiny-Baron G, Schlaeppi JM, Wood JM. Therapies directed at vascular endothelial growth factor. Expert Opin Investig Drugs 2002;11:1715-1736.
26. Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J. Angiogenesis inhibition by the novel VEGF tyrosine kinase inhibitor, PTK787/ZK222584, causes significant antiarthritic effects in models of rheumatoid arthritis. Inflamm Res 2004;53:133-142.
27. Kim WU, Kwok SK, Hong KH, Yoo SA, Kong JS, Choe J, Cho CS. Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. Arthritis Res Ther 2007;26:R42.
28. Choi ST, Kim JH, Seok JY, Park YB, Lee SK. Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 2009;3:333-337.
29. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007;282:26294-26305.
30. Fearon U, Veale DJ. Angiogenesis in arthritis: Methodological and analytical details. Methods Mol Med 2007;135: 343-357.
31. Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, Koukourakis MI. Upregulated hypoxia inducible factor-1a and -2a pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003;5:R193-R198.
32. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008;451:1008-1012.
33. Aljada A, O'Connor L, Fu YY, Mousa SA. PPARg ligands, rosiglitazone and pioglitazone inhibit bFGF- and VEGFmediated angiogenesis. Angiogenesis 2008;11:361-367.
34. Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of active psoriatic arthritis with the PPARg ligand pioglitazone: An open-label pilot study. Rheumatology 2005;44:126-129.
35. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T,Warner TD, Bishop-Bailey D. Activation of PPARb/d induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27:63-69.
36. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW. YC-1: A potential anticancer drug targeting hypoxiainducible factor 1. J Natl Cancer Inst 2003;95:516-525.
37. Hirota SA, Beck PL, MacDonald JA. Targeting hypoxiainducible factor-1 (HIF-1) signaling in therapeutics: Implications for the treatment of inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov 2009;3:1-16.
38. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-1998.
39. Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, Gaspar J, Goldring MB, Goldring SR, Oettgen P. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003;62:100-107.
40. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for surviving in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99: 4349-4354.
41. Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002;4: 201-208.
42. Chen Y, Donnelly E, Kobayashi H, Debusk LM, Lin PC. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 2005;52:1585-1594.
43. Yoo SA, Yoon HJ, Kim HS, Chae CB, De Falco S, Cho CS, KimWU. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: A link between angiogenesis and inflammation. Arthritis Rheum 2009;60:345-354.
44. Kameda H, Ishigami H, Suzuki M, Abe T, Takeuchi T. Imatinib mesylate inhibits proliferation of rheumatoid synovial fibroblast-like cells and phosphorylation of Gab adapter proteins activated by platelet-derived growth factors. Clin Exp Immunol 2006;144:335-341.
45. Koyama K, Hatsushika K, Ando T, Sakuma M, Wako M, Kato R, Haro H, Sugiyama H, Hamada Y, Ogawa H, Nakao A. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 2007;17:306-310.
46. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S-Y, Roczniak S, Shanafelt AB. The functional role of the ELR motif in CXC chemokinemediated angiogenesis. J Biol Chem 1995;270: 27348-27357.
47. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends Immunol 2007;28:299-307.
48. Pablos JL, Santiago B, Galindo M, Torres C, Brehmer M, Blanco FJ, Garcia-Lazaro FJ. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol 2003;170:2147-2152.
49. Calatozzolo C, Maderna E, Pollo B, Gelati M, Marras C, Silvani A, Croci D, Boiardi A, Salmaggi A. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 2006;5:827-832.
50. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96:34-40.
51. Stamatovic SM, Keep RF,Mostarica-Stojkovic M, Andjelkovic AV. CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J Immunol 2006;177:2651-2661.
52. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: A novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001;159:1521-1526.
53. Nanki T, Hayashida K, El-Gabalawy HS, Suson S, Shi K, Girschick HJ, Yavuz S, Lipsky PE. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4 + T-cell accumulation in rheumatoid arthritis synovium. J Immunol 2000;165:6590-6598.
54. Wente MN, Keane MP, BurdickMD, Friess H, BüchlerMW, Ceyhan GO, Reber HA, Strieter RM, Hines OJ. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006;241:221-227.
55. Zhang R, Tian L, Chen LJ, Hou JM, Li G, Li J, Zhang L, Chen XC, Luo F, Jiang Y, Wei YQ. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 2006;13:1263-1271.
56. Yin Y, Huang L, Zhao X, Fang Y, Yu S, Zhao J, Cui B. AMD3100 mobilizes endothelial progenitor cells in mice, but inhibits its biological functions by blocking an autocrine/ paracrine regulatory loop of stromal cell derived factor-1 in vitro. J Cardiovasc Pharmacol 2007;50:61-67.
57. Madri JA, Williams KS. Capillary endothelial cell cultures: Phenotypic modulation by matrix components. J Cell Biol 1983;97:153-165.
58. Szekanecz Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis. Regulation by cytokines and possible clinical importance. J Investig Med 1996;44: 124-135.
59. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004;4:432-444.
60. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;376: 517-519.
61. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264: 569-571.
62. HuangMT,Mason JC, Birdsey GM, Amsellem V, Gerwin N, Haskard DO, Ridley AJ, Randi AM. Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood 2005;106:1636-1643.
63. Naik TU, NaikMU, Naik UP. Junctional adhesion molecules in angiogenesis. Front Biosci 2008;13:258-262.
64. Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK, III, Imhof BA, Koch AE. Junctional adhesion molecule C mediates leukocyte adhesion to rheumatoid arthritis synovium. Arthritis Rheum 2008;58:3020-3039.
65. Jacq L, Garnier S, Dieudé P, Michou L, Pierlot C, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L, Lopes- Vaz A, Glikmans E, Barbet S, Lasbleiz S, Lemaire I, Quillet P, Hilliquin P, Teixeira VH, Petit-Teixeira E, Mbarek H, Prum B, Bardin T, Corné lis F. European Consortium on Rheumatoid Arthritis Families. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: A family-based study. Arthritis Res Ther 2007;9:R63.
66. Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther 2007;9:R112.
67. Kneilling M, Hültner L, Pichler BJ, Mailhammer R, Morawietz L, Solomon S, Eichner M, Sabatino J, Biedermann T, Krenn V, Weber WA, Illges H, Haubner R, Röcken M. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 2007;56:1806-1816.
68. McCarey DW, Sattar N, McInnes IB. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases? Arthritis Res Ther 2005;7:55-61.
69. Skotnicki JS, Zask A, Nelson FC, Albright JD, Levin JI. Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann NY Acad Sci 1999;878:61-72.
70. Szekanecz Z, Strieter RM, Koch AE. Cytokines in rheumatoid arthritis: Potential targets for pharmacological intervention. Drugs Aging 1998;12:377-390.
71. Brennan F, Beech J. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:296-301.
72. Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 2001;167:1644-1653.
73. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 1997;233:231-237.
74. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-a. Nature 1987;329: 630-632.
75. Markham T, Mullan R, Golden-Mason L, Rogers S, Bresnihan B, Fitzgerald O, Fearon U, Veale DJ. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006;54:1003-1012.
76. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoskizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48:1521-1529.
77. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR2- dependent angiogenesis. J Immunol 2005;175:6177-6189.
78. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ. Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 2006;54:3152-3162.
79. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003;93:321-329.
80. Morand EF, Leech M, Bernhagen J. MIF: A new cytokine link between rheumatoid arthritis and atherosclerosis. Nat Rev Drug Discov 2006;5:399-410.
81. Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Arthritis Res Ther 2004;6: R326-R334.
82. Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 2006;24:161-167.
83. Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: Rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 2007;9(Suppl. 2):S3.
84. Haq A, El-Ramahi K, Al-Dalaan A. Serum and synovial fluid concentrations of endothelin-1 in patients with inflammatory arthritides. J Med 1999;30:51-60.
85. Lee MS, Yoo SA, Cho CS, Suh PG, Kim WU, Ryu SH. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol 2006;177:5585-5594.
86. Mullan RH, Bresnihan B, Golden-Mason L, Markham T, O'Hara R, FitzGerald O, Veale DJ, Fearon U. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment and matrix degradation in rheumatoid arthritis through an NF-kB-dependent signal transduction pathway. Arthritis Rheum 2006;54:105-114.
87. Hong KH, Cho ML, Min SY, Shin YJ, Yoo SA, Choi JJ, Kim WU, Song SW, Cho CS. Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Clin Exp Immunol 2007;147:573-579.
88. Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK, III, Woods JM, Koch AE. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum 2006;54:2402-2414.
89. Haas CS, Amin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum 2007;56: 2535-2548.
90. Boulday G, Haskova Z, Reinders ME, Pal S, Briscoe DM. Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J Immunol 2006;176:3098-3107.
91. Maurer AM, Zhou B, Han ZC. Roles of platelet factor 4 in hematopoiesis and angiogenesis. Growth Factors 2006;24: 242-252.
92. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/ SLC through angiostatic and immunological mechanisms. J Immunol 2000;165:1992-2000.
93. Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 2003;74:282-290.
94. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
95. Komorowski J, Jerczyńska H, Siejka A, Barańska P, Ławnicka H, Pawłowska Z, Stepień H. Effect of thalidomide affecting VEGF secretion, cell migration, adhesion and capillary tube formation of human endothelial EA.hy926 cells. Life Sci 2006;78:2558-2663.
96. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. The effect of thalidomide and two analogs on collagen induced arthritis. J Rheumatol 1998;25:964-969.
97. Rico MC, Castaneda JL, Manns JM, Uknis AB, Sainz IM, Safadi FF, Popoff SN, Dela Cadena RA. Amelioration of inflammation, angiogenesis and CTGF expression ina n arthritis model by a TSP-1-derived peptide treatment. J Cell Physiol 2007;211:504-512.
98. Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM. Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 2004;165:2087-2098.
99. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-557.
100. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992; 175:1135-1138.
101. Hannig G, Bernier SG, Hoyt JG, Doyle B, Clark E, Karp RM, Lorusso J, Westlin WF. Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458. Arthritis Rheum 2007;56:850-860.
102. O'Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, Sems KM, Fernandez AM, Palmer WR, Klassen LW, Paulsen GA, Haire CE, Moore GF. Treatment of early seropositive rheumatoid arthritis: A two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum 2001;44:2235-2241.
103. Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? J Rheumatol 2003;30:2112-2122.
104. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin 2007;23: 515-522. (Pubitemid 46456899)
105. Nemoto K, Mae T, Abe F, Takeuchi T. Successful treatment with a novel immunosuppressive agent, deoxyspergualin, in type II collagen-induced arthritis in mice. Ann NY Acad Sci 1993;685:148-154.
106. Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF, Hannig G. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 2004;101: 10768-10773.
107. Yin G, Liu W, An P, Li P, Ding I, Planelles V, Schwarz EM, Min W. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002;5:547-554.
108. Takahashi H, Kato K, Miyake K, Hirai Y, Yoshino S, Shimada T. Adeno-associated virus vector-mediated antiangiogenic gene therapy for collagen-induced arthritis in mice. Clin Exp Rheumatol 2005;23:455-461.
109. Yue L, Shen YX, Feng LJ, Chen FH, Yao HW, Liu LH, Wu Q, Wang H. Blockage of the formation of new blood vessels by recombinant human endostatin contributes to the regression of rat adjuvant arthritis. Eur J Pharmacol 2007; 567:166-170.
110. Huang XY, Chen FH, Li J, Xia LJ, Liu YJ, Zhang XM, Yuan FL. Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis. Anat Rec (Hoboken) 2008;291: 1029-1037.
111. Kurosaka D, Yoshida K, Yasuda J, Yasuda C, Noda K, Furuya K, Ukichi T, Kingetsu I, Joh K, Yamaguchi N, Saito S, Yamada A. The effect of endostatin evaluated in an experimental animal model of collagen-induced arthritis. Scand J Rheumatol 2007;36:434-441.
112. Kurosaka D, Yasuda J, Yoshida K, Yasuda C, Toyokawa Y, Yokoyama T, Kingetsu I, Yamada A. Kinetics of circulating endothelial progenitor cells in mice with type II collagen arthritis. Blood Cells Mol Dis 2005;35:236-240.
113. Sumariwalla PF, Cao Y,Wu HL, Feldmann EM, Paleolog E. The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 2003;5:R32-R39.
114. Wang CR, Chen SY, Shiau AL, Wu CL, Jou IM, Chao L, Chao J. Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol 2007;34:2171-2176.
115. Mundel TM, Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 2007;74:85-89.
116. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-375.
117. Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, Plum SM. An angiogenesis inhibitor, 2-methoxyestradiol involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 2008;35: 2119-2128.
118. Issekutz AC, Sapru K. Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: An effect independent of an anti-angiogenic action. Int Immunopharmacol 2008;8: 708-716.